Junguo Bu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junguo Bu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Jingyu Li
Department of Pathology
2 shared publicationsYahui Yu
Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou City, Guangdong Province 510280, China
2 shared publicationsAimin Ji
Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, People's Republic of China
1 shared publicationAnan Xu
Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, People's Republic of China
1 shared publicationBaiyao Wang
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China
1 shared publicationChen Lin
Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in MedComm – Oncology
- Vol. 5 (3) , e70092
TRMT61A‐Mediated m1A Modification Suppresses FDX1 Translation to Drive Cuproptosis Evasion and Radioresistance in Hepatocellular Carcinoma
Radioresistance remains a major obstacle to the curative treatment of hepatocellular carcinoma (HCC). While cuproptosis represents a potential strategy to eliminate resistant cells, the epitranscriptomic mechanisms underlying cuproptosis evasion remain unclear. Here, we identified tRNA methyltransferase 61 A (TRMT61A)‐mediated N1‐methyladenosine (m1A) modification as an important mediator of radioresistance by suppressing cuproptosis. m1A dot blot assays and immunohistochemical analyses revealed increased mRNA m1A levels and TRMT61A expression in radioresistant HCC tumors, correlating with poor clinical outcomes. Using methylated RNA immunoprecipitation quantitative PCR (MeRIP‐qPCR), RNA pull‐down assays, and polysome profiling, we identified FDX1 mRNA as a preferential TRMT61A target and found that TRMT61A‐mediated m1A modification inhibited FDX1 protein production without altering mRNA abundance. RIP and luciferase reporter assays showed that YTHDF3 recognized m1A‐modified FDX1 transcripts and recruited eRF1 to repress translation. Functional assays revealed that FDX1 loss disrupted copper homeostasis and mitochondrial lipoylation, reducing radiotherapy‐induced cuproptosis. Targeting TRMT61A with the small‐molecule inhibitor CMP9 restored FDX1 translation, reactivated cuproptosis, and sensitized HCC tumors to radiotherapy in preclinical models, including patient‐derived xenografts. This study highlights a previously unrecognized epitranscriptomic axis wherein TRMT61A‐mediated m1A orchestrates cuproptosis evasion via translational repression of FDX1, and nominates TRMT61A‐mediated m1A modification as a therapeutic target for radioresistant HCC.
- 25 August 2026
- Published by Wiley in MedComm – Oncology
- Vol. 5 (3) , e70092
Open AccessTRMT61A‐Mediated m1A Modification Suppresses FDX1 Translation to Drive Cuproptosis Evasion and Radioresistance in Hepatocellular Carcinoma
Radioresistance remains a major obstacle to the curative treatment of hepatocellular carcinoma (HCC). While cuproptosis represents a potential strategy to eliminate resistant cells, the epitranscriptomic mechanisms underlying cuproptosis evasion remain unclear. Here, we identified tRNA methyltransferase 61 A (TRMT61A)‐mediated N1‐methyladenosine (m1A) modification as an important mediator of radioresistance by suppressing cuproptosis. m1A dot blot assays and immunohistochemical analyses revealed increased mRNA m1A levels and TRMT61A expression in radioresistant HCC tumors, correlating with poor clinical outcomes. Using methylated RNA immunoprecipitation quantitative PCR (MeRIP‐qPCR), RNA pull‐down assays, and polysome profiling, we identified FDX1 mRNA as a preferential TRMT61A target and found that TRMT61A‐mediated m1A modification inhibited FDX1 protein production without altering mRNA abundance. RIP and luciferase reporter assays showed that YTHDF3 recognized m1A‐modified FDX1 transcripts and recruited eRF1 to repress translation. Functional assays revealed that FDX1 loss disrupted copper homeostasis and mitochondrial lipoylation, reducing radiotherapy‐induced cuproptosis. Targeting TRMT61A with the small‐molecule inhibitor CMP9 restored FDX1 translation, reactivated cuproptosis, and sensitized HCC tumors to radiotherapy in preclinical models, including patient‐derived xenografts. This study highlights a previously unrecognized epitranscriptomic axis wherein TRMT61A‐mediated m1A orchestrates cuproptosis evasion via translational repression of FDX1, and nominates TRMT61A‐mediated m1A modification as a therapeutic target for radioresistant HCC.
- 26 May 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 827, 154043
O-GlcNAcylation of NSD2 promotes lung metastasis of triple-negative breast cancer through extracellular matrix remodeling
- 26 May 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 827, 154043
O-GlcNAcylation of NSD2 promotes lung metastasis of triple-negative breast cancer through extracellular matrix remodeling
- 9 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1871 (3) , 167665
Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway
- 9 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1871 (3) , 167665
Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway
- Open Access
- 8 February 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-11
A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer
Background. Cervical cancer (CC) is a common gynecological malignant tumor. Ferroptosis is a new type of programmed cell death, which plays a crucial part in cancer. However, current knowledge regarding ferroptosis-related long noncoding RNAs (lncRNAs) in CC is still limited. Therefore, our aim is to identify ferroptosis-related lncRNAs, build a steady prediction model, and improve the prediction value of CC. Methods. We obtained RNA expression and ferroptosis-related gene data of female CC patients from TCGA and FerrDb databases, respectively. Then, the ferroptosis-related lncRNAs were obtained by the limma R package and Cytoscape 3.7.1. We constructed the prediction model by Cox regression analysis. Finally, the prediction model was verified by the median risk score, KaplanMeier analysis, the time-dependent receiver operating characteristic (ROC) curve, clinical features, and immunoinfiltration analysis. Results. We acquired 1393 ferroptosis-related lncRNAs. The ferroptosis-related lncRNA signature was obtained by multivariate Cox regression analysis, and the patients were divided into a high-risk group and a low-risk group. The prognosis of the high-risk group was worse than that of the low-risk group. We found that the risk score can be used as an independent prognostic index by multivariate Cox regression analysis. The area under the time-dependent ROC curve reached 0.847 at 1 year, 0.906 at 2 years, 0.807 at 3 years, and 0.724 at 5 years in the training cohort. Principal component analysis showed that the diffusion directions of the two groups were different. Gene set enrichment analysis indicated that lncRNAs of two groups may be involved in tumorigenesis. Further analysis showed that high-risk groups were related to immune-related pathways. Ferroptosis-related lncRNAs are related to the proportion of tumor-infiltrating immune cells in CC. Conclusion. We have constructed a ferroptosis-related lncRNA prediction model. The prognostic model had important clinical significance, including improving the predictive value and guiding the individualized treatment of CC patients.
- 8 February 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-11
Open AccessA Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer
Background. Cervical cancer (CC) is a common gynecological malignant tumor. Ferroptosis is a new type of programmed cell death, which plays a crucial part in cancer. However, current knowledge regarding ferroptosis-related long noncoding RNAs (lncRNAs) in CC is still limited. Therefore, our aim is to identify ferroptosis-related lncRNAs, build a steady prediction model, and improve the prediction value of CC. Methods. We obtained RNA expression and ferroptosis-related gene data of female CC patients from TCGA and FerrDb databases, respectively. Then, the ferroptosis-related lncRNAs were obtained by the limma R package and Cytoscape 3.7.1. We constructed the prediction model by Cox regression analysis. Finally, the prediction model was verified by the median risk score, KaplanMeier analysis, the time-dependent receiver operating characteristic (ROC) curve, clinical features, and immunoinfiltration analysis. Results. We acquired 1393 ferroptosis-related lncRNAs. The ferroptosis-related lncRNA signature was obtained by multivariate Cox regression analysis, and the patients were divided into a high-risk group and a low-risk group. The prognosis of the high-risk group was worse than that of the low-risk group. We found that the risk score can be used as an independent prognostic index by multivariate Cox regression analysis. The area under the time-dependent ROC curve reached 0.847 at 1 year, 0.906 at 2 years, 0.807 at 3 years, and 0.724 at 5 years in the training cohort. Principal component analysis showed that the diffusion directions of the two groups were different. Gene set enrichment analysis indicated that lncRNAs of two groups may be involved in tumorigenesis. Further analysis showed that high-risk groups were related to immune-related pathways. Ferroptosis-related lncRNAs are related to the proportion of tumor-infiltrating immune cells in CC. Conclusion. We have constructed a ferroptosis-related lncRNA prediction model. The prognostic model had important clinical significance, including improving the predictive value and guiding the individualized treatment of CC patients.
- Open Access
- 1 February 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (4) , 126
PITPNC1 fuels radioresistance of rectal cancer by inhibiting reactive oxygen species production
Background: Neoadjuvant radiotherapy is a commonly used method for the current standard-of-care for most patients with rectal cancer, when the effects of radioresistance are limited. The phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1), a lipid-metabolism-related gene, has previously been proved to manifest pro-cancer effects in multiple types of cancer. However, whether PITPNC1 plays a role for developing radioresistance in rectal cancer patients is still unknown. Therefore, this study aims to investigate the role of PITPNC1 in rectal cancer radioresistance. Methods: Patient-derived tissue were used to detect the difference in the expression level of PITPNC1 between radioresistant and radiosensitive patients. Bioinformatic analyses of high-throughput gene expression data were applied to uncover the correlations between PITPNC1 level and oxidative stress. Two rectal cancer cell lines, SW620, and HCT116, were selected in vitro to investigate the effect of PITPNC1 on radioresistance, reactive oxygen species (ROS) generation, apoptosis, and proliferation in rectal cancer. Results: PITPNC1 is highly expressed in radioresistant patient-derived rectal cancer tissues compared to radiosensitive tissue; therefore, PITPNC1 inhibits the generation of ROS and improves the extent of radioresistance of rectal cancer cell lines and then inhibits apoptosis. Knocking down PITPNC1 facilitates the production of ROS while application of the ROS scavenger, N-acetyl-L-cysteine (NAC), could reverse this effect. Conclusions: PITPNC1 fuels radioresistance of rectal cancer via the inhibition of ROS generation.
- 1 February 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (4) , 126
Open AccessPITPNC1 fuels radioresistance of rectal cancer by inhibiting reactive oxygen species production
Background: Neoadjuvant radiotherapy is a commonly used method for the current standard-of-care for most patients with rectal cancer, when the effects of radioresistance are limited. The phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1), a lipid-metabolism-related gene, has previously been proved to manifest pro-cancer effects in multiple types of cancer. However, whether PITPNC1 plays a role for developing radioresistance in rectal cancer patients is still unknown. Therefore, this study aims to investigate the role of PITPNC1 in rectal cancer radioresistance. Methods: Patient-derived tissue were used to detect the difference in the expression level of PITPNC1 between radioresistant and radiosensitive patients. Bioinformatic analyses of high-throughput gene expression data were applied to uncover the correlations between PITPNC1 level and oxidative stress. Two rectal cancer cell lines, SW620, and HCT116, were selected in vitro to investigate the effect of PITPNC1 on radioresistance, reactive oxygen species (ROS) generation, apoptosis, and proliferation in rectal cancer. Results: PITPNC1 is highly expressed in radioresistant patient-derived rectal cancer tissues compared to radiosensitive tissue; therefore, PITPNC1 inhibits the generation of ROS and improves the extent of radioresistance of rectal cancer cell lines and then inhibits apoptosis. Knocking down PITPNC1 facilitates the production of ROS while application of the ROS scavenger, N-acetyl-L-cysteine (NAC), could reverse this effect. Conclusions: PITPNC1 fuels radioresistance of rectal cancer via the inhibition of ROS generation.
- Open Access
- 10 October 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (10) , 1-15
Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells
Radiotherapy is essential to treat breast cancer and microRNA (miRNA) miR-200c is considered as a radiosensitizer of breast cancer. However, the molecular mechanisms by which miR-200c regulates radiosensitivity remain largely unknown. In the present study, we showed that induction of miR-200c led to widespread alteration in long noncoding RNA (lncRNA) expression in breast cancer cells. We identified lncRNA LINC02582 as a target of miR-200c. Inhibition of LINC02582 expression increased radiosensitvity, while overexpression of LINC02582 promoted radioresistance. Mechanistically, LINC02582 interacts with deubiquitinating enzyme ubiquitin specific peptidase 7 (USP7) to deubiquitinate and stabilize checkpoint kinase 1 (CHK1), a critical effector kinase in DNA damage response, thus promoting radioresistance. Furthermore, we detected an inverse correlation between the expression of miR-200c vs. LINC02582 and CHK1 in breast cancer samples. These findings identified LINC02582 as a downstream target of miR-200c linking miR-200c to CHK1, in which miR-200c increases radiosensitivity by downregulation of CHK1.
- 10 October 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (10) , 1-15
Open AccessLong noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells
Radiotherapy is essential to treat breast cancer and microRNA (miRNA) miR-200c is considered as a radiosensitizer of breast cancer. However, the molecular mechanisms by which miR-200c regulates radiosensitivity remain largely unknown. In the present study, we showed that induction of miR-200c led to widespread alteration in long noncoding RNA (lncRNA) expression in breast cancer cells. We identified lncRNA LINC02582 as a target of miR-200c. Inhibition of LINC02582 expression increased radiosensitvity, while overexpression of LINC02582 promoted radioresistance. Mechanistically, LINC02582 interacts with deubiquitinating enzyme ubiquitin specific peptidase 7 (USP7) to deubiquitinate and stabilize checkpoint kinase 1 (CHK1), a critical effector kinase in DNA damage response, thus promoting radioresistance. Furthermore, we detected an inverse correlation between the expression of miR-200c vs. LINC02582 and CHK1 in breast cancer samples. These findings identified LINC02582 as a downstream target of miR-200c linking miR-200c to CHK1, in which miR-200c increases radiosensitivity by downregulation of CHK1.
- Open Access
- 1 January 2019
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 18
Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma
Due to the critical role of inflammation in nasopharyngeal carcinoma, we aim to investigate the correlation between nasopharyngeal carcinoma prognosis and the levels of tumor necrosis factor α and macrophages for the development of new prognostic models. The levels of tumor necrosis factor-α and CD68-positive macrophages were measured in 111 primary nasopharyngeal carcinoma specimens by immunohistochemistry. Kaplan-Meier analysis showed that, compared with nonelevated tumor necrosis factor-α levels, elevated tumor necrosis factor α levels were correlated with poorer 10-year distant metastasis-free survival (24.5% vs 5.2%, P = .004) and bone metastasis-free survival (17.0% vs 0.0%, P = .001). Multivariate analysis revealed that tumor necrosis factor α level was an independent prognostic factor for distant metastasis-free survival (hazard ratio = 16.765, P = .001), while the level of CD68-positive macrophages was a favorable independent prognostic factor for cancer-specific survival (hazard ratio = 0.481, P = .023) and disease-free survival (hazard ratio = 0.403, P = .010). Additionally, several prognostic models that considered tumor-node-metastasis stage alone or in combination with tumor necrosis factor α and/or CD68-positive macrophage levels were compared by receiver operating characteristic curve analysis. Interestingly, the T_score model, which considered the tumor necrosis factor α level alone, could better predict the distant metastasis-free survival and bone metastasis-free survival, whereas the MT model, which considered the combination of T stage and CD68-positive macrophage level, could better predict the cancer-specific survival and disease-free survival of patients with nasopharyngeal carcinoma. Elevated tumor necrosis factor-α levels and decreased CD68-positive macrophage levels in primary nasopharyngeal carcinoma tissues are unfavorable prognostic indicators in nasopharyngeal carcinoma. The T_score model or the MT model could be better prognostic models than those currently available for nasopharyngeal carcinoma and could be used to select high-risk patients and aid in the design of individualized immunotherapy.
- 1 January 2019
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 18
Open AccessElevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma
Due to the critical role of inflammation in nasopharyngeal carcinoma, we aim to investigate the correlation between nasopharyngeal carcinoma prognosis and the levels of tumor necrosis factor α and macrophages for the development of new prognostic models. The levels of tumor necrosis factor-α and CD68-positive macrophages were measured in 111 primary nasopharyngeal carcinoma specimens by immunohistochemistry. Kaplan-Meier analysis showed that, compared with nonelevated tumor necrosis factor-α levels, elevated tumor necrosis factor α levels were correlated with poorer 10-year distant metastasis-free survival (24.5% vs 5.2%, P = .004) and bone metastasis-free survival (17.0% vs 0.0%, P = .001). Multivariate analysis revealed that tumor necrosis factor α level was an independent prognostic factor for distant metastasis-free survival (hazard ratio = 16.765, P = .001), while the level of CD68-positive macrophages was a favorable independent prognostic factor for cancer-specific survival (hazard ratio = 0.481, P = .023) and disease-free survival (hazard ratio = 0.403, P = .010). Additionally, several prognostic models that considered tumor-node-metastasis stage alone or in combination with tumor necrosis factor α and/or CD68-positive macrophage levels were compared by receiver operating characteristic curve analysis. Interestingly, the T_score model, which considered the tumor necrosis factor α level alone, could better predict the distant metastasis-free survival and bone metastasis-free survival, whereas the MT model, which considered the combination of T stage and CD68-positive macrophage level, could better predict the cancer-specific survival and disease-free survival of patients with nasopharyngeal carcinoma. Elevated tumor necrosis factor-α levels and decreased CD68-positive macrophage levels in primary nasopharyngeal carcinoma tissues are unfavorable prognostic indicators in nasopharyngeal carcinoma. The T_score model or the MT model could be better prognostic models than those currently available for nasopharyngeal carcinoma and could be used to select high-risk patients and aid in the design of individualized immunotherapy.